

Autism Spectrum Disorder

## The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan

**Trial Status**  
Withdrawn

**Trial Runs In**  
0 Countries

**Trial Identifier**  
NCT03912350 WP41045

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared to healthy subjects with normal hepatic function matched by age ( $\pm 10$  years), sex, and body mass index (BMI;  $\pm 20\%$ ).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

**NCT03912350 WP41045**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
 $\geq 18$  Years &  $\leq 75$  Years

**Healthy Volunteers**  
Accepts Healthy Volunteers